Updated Pathology Considerations & Terminology in Mesothelioma-Updated Pathology Considerations & Terminology in Mesothelioma

Video Transcription

Video Summary

In the recent webinar organized by the Mesothelioma Subcommittee of the Rare Cancer Group from the EASLC, experts delved into updated pathology considerations and terminology in mesothelioma. Dr. Francois provided an overview of mesothelioma, a rare and aggressive cancer predominantly caused by asbestos exposure. Emphasizing the importance of histology, he explained how subtyping impacts prognosis and therapeutic strategies. The new WHO 2021 classification was discussed, highlighting the new concepts and terminologies introduced, such as mesothelioma in situ and classifications, distinguishing between benign, localized, and diffuse mesothelioma.<br /><br />Dr. Luca Brigg covered immunohistochemical staining crucial in differentiating mesothelioma from other tumors, stressing the importance of a detailed understanding of one's laboratory and the effects of pre-analytical variables on tests. Meanwhile, Dr. Andrew Churg focused on the challenges of distinguishing malignant mesothelioma from benign proliferations. He highlighted the importance of genomic testing, sharing insights on the relevance of detecting deletions or mutations in genes like BAP1, CDKN2A, MTAP, and NF2, using immunochemistry and FISH for precise diagnoses. The discussions underscored the significant advancements in the pathology of mesothelioma, offering promising avenues for precise diagnoses and improved therapeutic approaches.

Asset Subtitle

Video

Keywords

mesothelioma

asbestos exposure

histology

WHO 2021 classification

immunohistochemical staining

genomic testing

BAP1

CDKN2A

pathology advancements

therapeutic strategies